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Abstract
Objective: Peripheral protein biomarkers of Alzheimer’s disease (AD) may help
identify novel treatment avenues by allowing early diagnosis, recruitment to
clinical trials, and treatment initiation. The purpose of this review was to deter-
mine which proteins have been found to be differentially expressed in the AD
brain and whether these proteins are also found within the blood of AD
patients. Methods: A two-stage approach was conducted. The first stage
involved conducting a systematic search to identify discovery-based brain pro-
teomic studies of AD. The second stage involved comparing whether proteins
found to be differentially expressed in AD brain were also differentially
expressed in the blood. Results: Across 11 discovery based brain proteomic
studies 371 proteins were at different levels in the AD brain. Nine proteins were
frequently found, defined as appearing in at least three separate studies. Of
these proteins heat-shock cognate 71 kDa, ubiquitin carboxyl-terminal hydro-
lase isozyme L1, and 20,30-cyclic nucleotide 30 phosphodiesterase alone were
found to share a consistent direction of change, being consistently upregulated
in studies they appeared in. Eighteen proteins seen as being differentially
expressed within the AD brain were present in blood proteomic studies of AD.
Only complement C4a was seen multiple times within both the blood and brain
proteomic studies. Interpretation: We report a number of proteins appearing
in both the blood and brain of AD patients. Of these proteins, C4a may be a
good candidate for further follow-up in large-scale replication efforts.
Introduction
The World Health Organisation (WHO) describes
dementia as a syndrome in which memory, thinking,
behavior, and the ability to perform everyday activities
deteriorate irreversibly. The most common form of
dementia is Alzheimer’s disease (AD) which presently
affects over 35 million individuals globally, and is pre-
dicted to affect 115 million people worldwide by 2050.1
The total cost of the condition to the UK economy is
estimated to be £26.3 billion annually.2
At postmortem the brain of AD patients presents with
neurodegeneration mostly affecting the medial temporal
lobe and neocortical structures.3 AD is characterized
pathologically by accumulation of amyloid beta (Ab) pep-
tides, seen as senile plaques, and hyper-phosphorylated
Tau protein apparent as neurofibrillary tangles. The pre-
cise triggers for their appearance and propagation remain
uncertain. It is therefore unsurprising that management
of AD is problematic. A definitive diagnosis of AD can
only be made at autopsy when these neuropathological
changes are visible. The clinical diagnosis of AD in the
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living patient is a diagnosis of probability presently. It
relies upon a combination of history taking, especially
from family members, and either a mental status exami-
nation or neuropsychological testing.4 Mental status
examination involves the condensed mini-mental state
exam and the more thorough Addenbrooke’s Cognitive
Examination being performed. These examinations sug-
gest the presence of dementia but not the specific type,
therefore requiring further investigations. Pharmacologi-
cal treatment revolves around symptomatic relief. Pre-
sently no medication exists that modifies the course of
the disease by directly acting on the responsible patho-
logical mechanisms. A number of disease modifying
agents are the intense focus of research, although to date
many have been found to be ineffective in clinical tri-
als.5
Against this background protein biomarkers of AD are
assuming increasing importance. A biomarker that corre-
sponds to the early stages of AD would enable the initia-
tion of earlier treatment of this slowly progressing
condition, and thus maximize the chances of successful
treatment therapy. This could be achieved by identifying
patients at an earlier stage of their AD and recruiting
them into clinical trials at a point where it is more likely
that novel agents will be more effective. The cerebrospinal
fluid (CSF) is in direct contact with brain tissue and pro-
vides insight into changes experienced by the brain.6 A
well-validated finding for the prediction of AD that dis-
plays sensitivity and specificity is that the CSF of affected
patients sees a reduction in the levels of Ab42, but
increased total and phosphorylated Tau levels.7 A lumbar
puncture, required to extract CSF, is an invasive proce-
dure and thus is far from ideal. Neuroimaging is an alter-
native method for identifying protein biomarkers.
Compounds have been developed that pick up Ab42
deposits in the living brain of sufferers such as the Pitts-
burgh Compound B, and the FDDNP compound which
also binds to Tau proteins.3 But their use is expensive
and not routine.
Researchers are increasingly turning to peripheral blood
protein markers in an attempt to eventually create a sim-
ple and cheap blood test that could help clinicians to pick
up this disease at the earliest stage possible. The first stage
in this process is to identify the AD biomarkers in the
blood, and such progress within the field has been
recently reviewed.8 This review has shown a wide diversity
of methods have been applied to this task, but that unfor-
tunately few of the hypothesized biomarkers show cross
study replication. However, five proteins were found to
have associated with AD-related phenotypes in five inde-
pendent studies. Whether and how potential blood
biomarkers relate to AD pathology in the brain is largely
unknown.
A thorough and systematic analysis of protein levels in
brain samples of individuals who had AD will be infor-
mative by helping to highlight proteins affected by AD.
The proteins whose levels differ most between AD and
control brains warrant further research to determine their
relationship to pathology and their potential as biomark-
ers in blood. Furthermore, comparison to the peripheral
protein markers already identified will help to determine
which peripheral markers are most plausibly related to
neurodegeneration. The purpose of this review is to
address these issues and to synthesize the information in
the hope that future large-scale replication efforts can be
focused on markers which reflect AD pathology both in
the blood and brain.
Methods and Materials
This systematic review comprised two aspects: (1)
whether proteins were at different levels in the AD brain
relative to control brains; and (2) whether proteins at dif-
ferent levels in AD brains were also at different levels in
AD blood samples.
Differential expression in Alzheimer’s
disease brain samples
To identify relevant studies a systematic search strategy
was conducted in PubMed in December 2014. The
phrases “Alzheimer* disease,” “human brain,” and “pro-
teomics” were used and combined with the operative
“AND” to return suitable results. To warrant inclusion
the study must have been discovery based (i.e., untargeted
proteomics) rather than candidate-based in its approach.
This review set out to identify proteins that were at dif-
ferent levels in AD brains as compared to control brains,
that is, was the overall level of a protein the same in both
AD and control brains, or was it significantly up or
downregulated? As such, we limited our findings to pro-
teins displaying this type of change in AD versus control
studies. Consequently, studies focusing on specific bio-
chemical modifications occurring to a protein such as
oxidation, nitrosylation, and phosphorylation were
excluded. In the interests of accuracy and reproducibility
of results, only proteins that could be traced back to a
specific UniProt ID were included. Finally, to maximize
the yield of studies returned from the PubMed search, no
specific date range was specified.
Differential expression in Alzheimer’s
disease blood samples
A recent systematic review conducted by Chiam et al.9
compiled a list of blood protein biomarkers of AD from
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studies of plasma, serum and leukocyte proteins. Their
approach consisted of discovery, rather than candidate,
based studies with exceptions made for panel-based stud-
ies including over 100 candidate proteins. This data was
further reviewed and amended to remove duplicate pro-
tein listings found. Subsequently, proteins identified to be
at different levels in AD brain versus control brain sam-
ples were compared to this list to ascertain proteins that
were also associated with AD-related phenotypes in
blood.
Statistical analysis
The significance of overlapping protein lists was assessed
using a hypergeometric test performed in R.
Results
AD brain proteins
The initial literature search returned a total of 281 papers
matching our search terms. These papers were analyzed
through a manual search of their abstracts to identify
potentially useful studies. This yielded a total of 28 papers
appearing to fulfill the inclusion criteria. The results were
then further refined to include only 14 papers, by exclud-
ing studies focusing on posttranslational modifications of
proteins and studies unable to be identified via a specific
UniProt ID. At the time of writing, three papers10–12
could not be sourced and were not included in the final
analysis. Thus the final number of studies selected
was 11,13–23 with principle brain tissue sites being cortex,
hippocampus, and substantia nigra (Table S1). The
numbers of papers encountered at each stage of the litera-
ture search is displayed in Figure 1.
A total of 371 proteins across 11 studies were found to
be at different levels in AD brain samples in at least one
study (Table S2). The most frequently found proteins
across studies are shown in Table 1. A protein was deemed
to be frequently found if it appeared in three or more
studies. The most frequently found proteins with a consis-
tent direction of change were heat-shock cognate 71 kDa
protein, ubiquitin carboxyl-terminal hydrolase isozyme L1,
and 20,30-cyclic nucleotide 30 phosphodiesterase.
AD blood proteins
Chiam et al. identified 23 papers25–43, 57–60 comprising 18
independent research cohorts and 179 potential blood-
based protein biomarkers.9 These results were verified and
duplicates found within this study were discarded, giving
a total of 176 proteins. The overlap between these 176
proteins and the 371 identified proteins differentially
expressed in AD brain amounted to a total of 18 proteins
(Fig. 2). The direction of association within the overlap
Figure 1. Literature search tree describing the process implemented
to source papers for this review. Out of a total of 281 papers
identified through database search 11 papers were selected for
inclusion.
Table 1. Proteins identified as being the most frequently found pro-
teins from 11 postmortem brain studies of Alzheimer’s disease
patients.
4/11 Studies 3/11 Studies
Creatine kinase B-type13,17–19
(Protein downregulated,13
Protein upregulated17–19)
Heat-shock cognate
71 kDa protein13,18,20
(Protein upregulated13,18,20)
Glial fibrillary acidic
protein13,19,21,23
(Protein downregulated,13,23
Protein upregulated,19,23
Direction not reported21)
Ubiquitin carboxyl-terminal
hydrolase isozyme L118–20
(Protein upregulated18,19,20)
14-3-3 Protein epsilon13,16,17
(Protein downregulated,16
Protein upregulated13,17)
Dihydropyrimidinase-related
protein13,20,23
(Protein downregulated,20,23
Protein upregulated13)
Glyceraldehyde-3-phosphate
dehydrogenase13,19,20
(Protein downregulated,13,19
Protein upregulated20)
20,30-Cyclic nucleotide 30
phosphodiesterase16,20,22
(Protein upregulated16,20,22)
Alphainternexin15,19,23
(Protein downregulated,19,23
Protein upregulated15)
A protein was deemed to be frequently found if it was present in at
least three of the 11 studies.
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was not considered, this was motivated by the negative
association of brain and CSF amyloid beta.24
Analysis of the probability of achieving such an overlap
by chance alone requires knowledge of the background
set, that is, the set of all proteins that could have been
detected using the proteomic approaches applied. This is
often not known for a specific proteomic approach, and
is definitely not known over a wide-range of different
proteomic approaches in different tissues (blood and
brain). The overlap was not found to be significant at the
0.05 level (P ~ 1) when using a conservative estimate of
the size of the background set (n = 20,000).
Table S3 displays the 18 proteins shared between both
blood and brain studies. Two proteins frequently found
within the brain studies, 14-3-3 protein epsilon and glyc-
eraldehyde-3-phosphate, were found to also be present in
the blood studies (Table 2). Only complement C4-A
occurred multiple times in both blood and brain studies,
appearing in three blood studies30,32,36 and two brain
studies.14,17
Discussion
The results of our study identify proteins that appear to
be associated with AD in both the brain and blood. AD is
a complex condition and as such it was perhaps foresee-
able that a large number of proteins would be found to
be at different levels in AD brain as compared to control
brain samples. However, it was encouraging to see a
number of brain proteins replicated between studies
despite the small sample size and lack of multiple testing
corrections of some studies. It was also promising to see
proteins appearing in both blood and brain studies.
It is intriguing that there is an agreement, however
small, between the two types of studies, that is, some pro-
teins are associated with AD in both the brain and the
blood. This is either a sign that some proteins level in
multiple tissues (brain and blood) are associated, or could
be purely coincidental. Consistent with the possibility that
findings are coincidental, the size of the overlap in pro-
teins associated with AD in the brain and blood was not
found to be greater than you would expect by chance.
However, this analysis is greatly limited by our knowledge
of the proteins detectable using these proteomic
approaches on samples from these tissues. If instead the
proteins level in the blood and brain are truly associated
this could be direct – brain levels influencing blood levels
or vice versa; or indirect – that their levels are con-
founded by another factor, for example, AD medication
or inflammation. While an indirect link is more likely,
the possibility of a direct link needs further consideration.
Ordinarily, the brain is segregated from the vascular
system through the blood–brain barrier (BBB). Any
exchange of material between the two is minimal and
dependent upon specialized transporters. Such an
arrangement ensures the brain is well protected from the
volatility of the vascular environment. Dysfunction of this
important barrier may occur in AD. For example, it has
been shown that the BBB begins to breakdown during
normal aging starting in the hippocampus, an area of
early AD pathology. This breakdown was shown to
increase in Mild Cognitive Impairment, which sometimes
leads to AD.44 Studies have shown blood-derived toxins
to accumulate in postmortem AD,45 and in at least a sub-
set of AD patients histological, radiological, and CSF
albumin abnormalities have been reported suggesting BBB
impairment.46 If indeed the BBB is disrupted in AD then
this could provide a direct route whereby proteins pass
from the brain to the bloodstream (or vice versa) in suffi-
cient quantities as to be detectable. This may explain the
association between brain and blood studies that we have
Figure 2. Number of proteins identified in discovery studies
associating with Alzheimer’s disease (AD) in postmortem brains or
AD-related measures in blood samples. Venn diagram, to approximate
scale, is used to demonstrate the overlap. A protein was deemed to
be highly replicated if it appeared in 3 or more studies.
Table 2. Proteins identified as being differentially expressed from
blood studies of Alzheimer’s disease (AD) patients and brain studies
of AD patient’s.
Protein UniProt ID
Brain
studies
Blood
studies
14-3-3 protein epsilon P62258 313,16,17 143
Glyceraldehyde-3-phosphate
dehydrogenase
P04406 313,19,20 143
Calcium/calmodulin-dependent
protein kinase
type II subunit alpha
Q9UQM7 213,22 140
Complement C4-A P0C0L4 214,17 330,32,36
Gelsolin P06396 217,22 142
Proteins appearing in at least two brain studies that also appear in at
least one blood study are shown. The full list of proteins seen in both
types of studies can be seen in Table S3.
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found. In this scenario the identities of proteins compara-
ble across studies would assume great importance as they
may be involved in AD pathology.
Complement c4a (C4A) was the only protein to associ-
ate with AD multiple times in the blood and brain
(Table 2). Encouragingly, this protein was upregulated in
the cortex of both brain studies it appeared in; reassur-
ingly both of these studies had employed multiple testing
corrections (Table S1). C4A is a known marker of inflam-
mation and a feature seen within AD is chronic inflam-
mation, whether occurring primarily as part of the disease
or as the body’s response to the pathological effects of
AD.47 This result is therefore in line with current thinking
on pathophysiological mechanisms occurring in AD.
However, in itself this protein is likely to be fairly non-
specific. Plasma immune markers are affected by different
storage methods, concomitant infections and inflamma-
tory illnesses.48 Furthermore, the direction of C4A’s asso-
ciation within the blood studies was not consistent, with
it being reported as downregulated,32 upregulated30 or
unknown36 in the three peripheral studies it featured in.
It is therefore difficult to distinguish whether this protein
is coming from the AD brain, is a non-specific indicator
of AD pathology, or arose as a result of co-morbidity. As
such, in isolation its value as a peripheral biomarker may
be limited, but perhaps when used in conjunction with
other peripheral markers may be more useful. Indeed, it
has previously been suggested that C4A may be used in
this way.32 Conceivably, a future blood test could act as a
prescreening tool to signal the presence of neuropatholog-
ical changes that can then be investigated further with
more specific diagnostic tools such as lumbar punctures
or brain scans.
The classical hallmarks of AD brain at postmortem are
senile plaques, due to amyloid beta (Ab) deposition, and
neurofibrillary tangles subsequent to tau dysfunction.
However, in our review tau is only found to associate
with AD in one independent cohort, whereas Ab was
found to associate with AD in just two independent
cohorts. While initially surprising, this is likely to be due
to the known limitations of the discovery proteomic
approaches applied, which may not be capable of accu-
rately quantifying the level of these proteins.
Contrastingly, we report three brain proteins (heat-
shock cognate 71 kDa protein [HSC70], ubiquitin
carboxyl-terminal hydrolase isozyme L1 [UCHL1], and
20,30-cyclic nucleotide 30 phosphodiesterase [CNPase])
that were consistently upregulated in all brain studies that
they appeared in (Table 1). These results should be trea-
ted with caution as none of these studies used multiple
testing corrections, but the repeated findings do suggest
they are worth retesting in larger studies. HSC70 belongs
to the heat shock 70 family of proteins that serves to
protect neurons from protein aggregation and toxicity. It
has recently been suggested that HSC70 slows down the
rate of tau clearance in the AD brain49 which perhaps
explains its consistent upregulation. Previously it had
been said that downregulation of HSC70 is responsible
for the impaired protein clearance seen in the AD brain.50
UCHL1 is a deubiquinating enzyme and over-expression
has been shown to delay AD progression in vivo,51
although low levels have been reported in postmortem
brain tissue from AD patients.52 CNPase plays a role in
the synthesis and maintenance of myelin membranes with
decreased levels reported in AD.53 With this in mind, it is
positive that these three brain proteins share a consistent
direction of association across our reviewed studies, but
there is some discrepancy with regards to previously
reported directions (see above). This incongruity may be
because of a lack of multiple testing correction in these
studies. These proteins were also not confined to a speci-
fic area of the brain. For example, HSC70 and CNPase
were found within the substantia nigra, cortex and
hippocampus sites, whereas UCHL1 was found in the
hippocampus and cortex (Table S1).
Creatine-kinase B type (CKB) is another promising but
inconsistent candidate. This was one of the most fre-
quently found proteins within the brain studies. CKB was
reported to be upregulated in three studies (importantly
one of these three studies did correct for multiple testing)
and downregulated in one study (which did not correct
for multiple testing). With this in mind it is conceivable
that CKB is another protein, that is, consistently upregu-
lated within the AD brain. CKB has a vital role in the cel-
lular energetics of the brain and is highly expressed
within the hippocampus, an area of the brain critically
affected in AD.54 However, it is not known to have a
direct link to AD pathology.
A lot of the reviewed findings may simply be coinci-
dental. Strengthening this viewpoint is the observation
that very few proteins were seen multiple times as being
differentially expressed in AD brain samples, and that
directions of association were sometimes inconsistent.
This has also been seen in a review of blood protein
markers of AD.8 Large methodological limitations (e.g.,
small sample size, and lack of multiple testing correc-
tions) and study differences (e.g., proteomic approaches,
postmortem time in processing brain tissue, and physio-
logic differential expression of proteins at sites) may be
the culprit with regards to this issue of replicability. The
gold standard of AD diagnosis remains postmortem anal-
ysis of the brain and our results are derived from such
studies. However, the blood studies reviewed by Kiddle
et al.8 and Chiam et al.9 are obtained from living
patients given a clinical diagnosis of AD. This difference
in diagnosis between blood and brain studies (i.e.,
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clinical vs. postmortem confirmed) represented a
methodological difference that should be considered
when interpreting results as there is a possibility that
some of the blood results were from patients misdiag-
nosed as having AD.
It is also disappointing that information about the
severity of AD along with comorbid status was not
reported within brain studies (Table S1). This is signifi-
cant as early AD differs from late AD with regards to
inflammatory profiles of the brain55 and within the stud-
ies there is likely heterogeneity of disease severity. Also,
the burden of comorbid neurological disorders is higher
within the elderly population56 with each condition
affecting protein expression.9 These limitations prevent
truer comparisons being made. Moreover, only 3/11 of
the studies reviewed used multiple testing corrections to
determine differential expression suggesting many hypoth-
esized markers may be false positives. This could be
investigated using specific follow-up experiments.
Finally, we have focused on the blood–brain compar-
ison as a systematic review on blood based protein mark-
ers of AD has already been performed by this group.8
Furthermore, if a blood protein marker of AD were to be
found then this would have a significant impact on the
research community. However, an important aspect that
needs consideration is whether there is overlap of proteins
present within the brain and CSF of AD patients, as the
CSF more intimately represents neuronal changes. Future
studies reviewing this particular facet will likely further
inform the field.
Conclusion
We have reviewed a large number of proteins whose levels
in the brain appear to associate with AD. A few proteins
in postmortem brain samples were seen to associate with
AD across multiple studies. In addition the level of some
of these proteins in blood samples have already been
shown to associate with AD-related phenotypes, suggest-
ing a possible link between their levels in brain and blood
in response to AD. However, the robustness of these links
has not been sufficiently tested, especially not within a
single study. Large-scale replication efforts are needed to
clarify these links and to establish whether proteins found
herein are specific to AD.
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